Alder BioPharmaceuticals® to Present at the Canaccord Genuity 38th Annual Growth Conference
BOTHELL, Wash., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Robert W. Azelby, Alder’s president and chief executive officer, at the Canaccord Genuity 38th Annual Growth Conference at 2:30 p.m. ET on Thursday, August 9, 2018 in Boston, MA.
A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for at least 30 days after the live event concludes.
About Alder BioPharmaceuticals, Inc.Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP). Eptinezumab is currently in late-stage clinical development and, if approved, will be the first-to-market infusion therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, visit www.alderbio.com.
Investor Relations Contacts:Ashwin AgarwalVice President, Corporate StrategyAlder Biopharmaceuticals, Inc.425-408-8567 email@example.com
Michael SchaffzinStern Investor Relations, Inc.212-362-1200 firstname.lastname@example.org
Media Contact: Ashley Cadle TogoRun email@example.com 310.463.0143